Antibody variant and isoform with lowered biological activity

Patent metadata

Field	Value
Publication number	US-2020283544-A1
Application number	US-201816758128-A
Country	US
Kind code	A1
Filing date	Oct 31, 2018
Priority date	Nov 1, 2017
Publication date	Sep 10, 2020
Grant date	—

Abstract

As antibody variants and isoforms having reduced FVIII mimetic activity than Emicizumab, the antibody variants having some specific amino acid residues in the variable region cleaved out and missing (Q-CDR-Clipped Variants) and the antibody isoforms having inter-heavy chain disulfide bonds less susceptible to reduction under mild reducing conditions (Protected Disulfide Isoforms) are provided.

First claim

1 . A variant of an antibody that comprises a variable region comprising the amino acid sequence SISPSGQSTYYRREVKG (SEQ ID NO: 2), wherein
(a) the amino acid residue R at the 12th position from the N terminus side of the sequence; or (b) the amino acid residues YYR at the 10th to 12th position from the N terminus side of the sequence,
is deleted and the variable region is cleaved at the deletion site.

2 . The antibody variant of claim 1 , wherein the sequence is a CDR sequence.

3 . The antibody variant of claim 1 , wherein the sequence is a CDR2 sequence.

4 . The antibody variant of claim 1 , wherein the sequence is a sequence comprised in a heavy chain.

5 . The antibody variant of claim 1 , which is a variant of a bispecific antibody.

6 . The antibody variant of claim 1 , which is a variant of Emicizumab.

7 . A method for detecting the antibody variant of any one of claims 1 to 6 , comprising the step of separating a sample containing an antibody that comprises a variable region comprising the amino acid sequence SISPSGQSTYYRREVKG (SEQ ID NO: 2) by affinity chromatography, ion exchange chromatography, normal phase chromatography, reverse phase chromatography, hydrophilic interaction chromatography (HILIC), hydrophobic interaction chromatography (HIC), separation based on charge, size exclusion chromatography (SEC), gel permeation chromatography (GPC), or combinations thereof.

8 . The method for detecting of claim 7 , which uses the antibody variant of any one of claims 1 to 6 as a reference standard.

9 . A pharmaceutical composition comprising the antibody variant of any one of claims 1 to 6 , wherein the percentage of the antibody variant in the total antibody molecules in the pharmaceutical composition is 5% or less.

10 . The pharmaceutical composition of claim 9 , wherein the antibody is Emicizumab.

11 . The pharmaceutical composition of claim 9 , which is obtained by a purification process comprising purification by cation exchange chromatography (CEX).

12 . A method for suppressing production of the antibody variant of any one of claims 1 to 6 , comprising the step of culturing antibody producing cells at a pH of 7.1 or more, and/or at a culture temperature of 36° C. or less.

13 . An isoform of a bispecific antibody comprising a first heavy chain and a second heavy chain, wherein
disulfide bonds are formed in the following:
(1a) between cysteine at position 144 according to EU numbering of the first heavy chain and cysteine at position 200 according to EU numbering of the second heavy chain; and
(1b) between cysteine at position 200 according to EU numbering of the first heavy chain and cysteine at position 144 according to EU numbering of the second heavy chain, or wherein
disulfide bonds are formed in the following:
(2a) between cysteine at position 226 according to EU numbering of the first heavy chain and cysteine at position 229 according to EU numbering of the second heavy chain; and
(2b) between cysteine at position 229 according to EU numbering of the first heavy chain and cysteine at position 226 according to EU numbering of the second heavy chain.

14 . The bispecific antibody isoform of claim 13 , wherein disulfide bonds are formed in (1a) and (1b).

15 . An isoform of a bispecific antibody comprising a first heavy chain and a second heavy chain, characterized in that it elutes at a region more to the alkaline side than the bispecific antibody when separated using cation exchange chromatography.

16 . The bispecific antibody isoform of any one of claims 13 to 15 , which is an isoform of Emicizumab.

17 . A method for detecting the antibody isoform of any one of claims 13 to 16 , comprising the step of separating a sample containing a bispecific antibody by affinity chromatography, ion exchange chromatography, normal phase chromatography, reverse phase chromatography, hydrophilic interaction chromatography (HILIC), hydrophobic interaction chromatography (HIC), separation based on charge, size exclusion chromatography (SEC), gel permeation chromatography (GPC), or combinations thereof.

18 . The method for detecting of claim 17 , which uses the antibody isoform of any one of claims 13 to 16 as a reference standard.

19 . A pharmaceutical composition comprising the bispecific antibody isoform of any one of claims 13 to 16 , wherein the percentage of the antibody isoform in the total antibody molecules in the pharmaceutical composition is 2% or less.

20 . A method for reducing the content percentage of the bispecific antibody isoform of any one of claims 13 to 16 , comprising the step of purification by cation exchange chromatography.

21 . The antibody isoform or variant of claim 1 , 13 , or 15 , wherein the biological activity of the antibody is markedly reduced.

Assignees

• Chugai Pharmaceutical Co Ltd

Inventors

• Hosoguchi Kensaku
• Kuwayama Maki
• Seida Chifumi
• Watanabe Yosuke
• Tanaka Nobuyuki
• Saitoh Satoshi
• Fukuda Masakazu

Classifications

• G01N33/575

  for cancer · CPC title

• A61K39/395 Primary

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• C07K16/46 Primary

  Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00) · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title